Sue Desmond-Hellmann | |
---|---|
Born | 1958 (age 65–66) Napa, California, U.S. |
Education | University of Nevada, Reno (BS, MD) University of California, Berkeley (MPH) |
External audio | |
---|---|
“Pandemic Perspectives: Interview with Sue Desmond-Hellmann”, May 14, 2020, Science History Institute. |
Sue Desmond-Hellmann (born 1958) is an American oncologist and biotechnology leader who served as the Chief Executive Officer of the Bill & Melinda Gates Foundation from 2014 to 2020. In March 2024 she was elected as a board member of OpenAI. She was previously Chancellor of the University of California, San Francisco (UCSF), the first woman to hold the position, and Arthur and Toni Rembe Rock Distinguished Professor, and before that president of product development at Genentech, where she played a role in the development of the first gene-targeted cancer drugs, Avastin and Herceptin. [1]
Born in Napa, California, [2] Desmond-Hellmann grew up in Reno, Nevada, as one of seven children. Her father worked as a pharmacist and her mother was an English teacher. [3] She graduated from Bishop Manogue High School in 1975. [4] She earned a bachelor of science degree in pre-medicine and an M.D. from the University of Nevada, Reno and received her residency training at UCSF, where she served as chief resident. She is board-certified in internal medicine and medical oncology, and also holds a master's degree in public health from the University of California, Berkeley School of Public Health. [5]
Desmond-Hellmann served as an associate adjunct professor of epidemiology and biostatistics At UCSF. She joined the UCSF medical faculty during the HIV/AIDS epidemic in San Francisco, and worked on Kaposi's sarcoma. Beginning in 1989 both she and her husband, an infectious disease doctor, spent two years as visiting faculty at the Uganda Cancer Institute, studying and treating patients with infectious diseases and Kaposi's sarcoma in a project funded by the Rockefeller Foundation. [5] [3] She then spent two years in private practice.
Returning to clinical research, Desmond-Hellmann became associate director of clinical cancer research at Bristol-Myers Squibb Pharmaceutical Research Institute. While there, she was the project team leader for Taxol.
In 1995, Desmond-Hellmann joined Genentech as a clinical scientist. She was named chief medical officer the following year, and in 1999 became executive vice president of development and product operations. From March 2004 through April 2009 she was president of product development, playing a role in the development of two of the first gene-targeted therapies for cancer, Avastin and Herceptin. [3] [5] [6] She left after the company was acquired by Roche Pharmaceuticals. [3] [7] At that point her compensation was $8 million a year. [3]
From 2005 to 2008, Desmond-Hellmann served a three-year term as a member of the American Association for Cancer Research board of directors, and from 2001 to 2009, she served on the executive committee of the board of directors of the Biotechnology Industry Organization. She also served a three-year term on the Economic Advisory Council of the Federal Reserve Bank of San Francisco beginning in January 2009. [5] She served on the corporate board of Affymetrix from 2004 to 2009 [5] and on the board of Procter & Gamble in 2012–2013. [8]
After being invited to apply, on August 3, 2009, Desmond-Hellmann became the ninth Chancellor of UCSF, and the first woman to hold the position. [9] Desmond-Hellmann became the first Chancellor drawn from outside academia. Her starting salary was $450,000 a year. [3]
In June 2010, one day after being questioned by The New York Times , Desmond-Hellmann sold her stock in the Altria Group, which owns Phillip Morris USA and other tobacco companies, and subsequently donated $134,000 to the tobacco control center at UCSF. She said that many of her holdings had been purchased on her behalf by her stockbroker and that she was too busy to oversee all her investments, although she had included the stock on her financial disclosure statement. [10] [11]
In January 2012, Desmond-Hellmann proposed changing the relationship between UCSF, a health sciences university, and the University of California. [12] She proposed creating partnerships between UCSF and private pharmaceutical corporations and other sources of funding, in order to increase its revenues and resolve its projected financial instability. [3] [7] [13] [14]
Desmond-Hellmann served as UCSF Chancellor until March 2014, holding the Arthur and Toni Rembe Rock Distinguished Professorship during her tenure. [5]
In 2011, Desmond-Hellmann co-chaired a National Academy of Sciences committee that recommended creating a Google Maps-like data network aimed at developing more diagnostics and treatments tailored to individual patients — a concept known as precision medicine. [15] The so-called "knowledge network" would integrate the wealth of data emerging on the molecular basis of disease with information on environmental factors and patients’ electronic medical records and would allow scientists to share emerging research findings faster, thereby accelerating the development of tailored treatments. It also would allow clinicians to make more informed decisions about treatments, reduce health care costs and ultimately improve care. [16] The NAS report, titled "Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease", was described by Keith Yamamoto, Vice Chancellor for Research at UCSF, as "the most important National Academy of Sciences Framework Analysis since that advisory body recommended that the United States go forward with the Human Genome Project". [17]
On December 17, 2013, The Bill & Melinda Gates Foundation announced that it had selected Desmond-Hellmann as its next chief executive officer. [15] [6] She assumed her role on May 1, 2014, the first head of the foundation to be neither a former Microsoft executive nor a personal friend of the Gates', and the first physician. [18]
In 2017, Desmond-Hellmann became a member of the Prix Galien USA Committee, [19] succeeding Roy Vagelos as Chair of that Committee in 2018. She is also Chair of the Prix Galien International and Member of the Prix Galien Africa Committee.
In December 2019, Desmond-Hellmann announced plans to step down from her role as BMGF CEO "for health and family reasons". Mark Suzman will leave his role of BMGF president of Global Policy & Advocacy and chief strategy officer to become the new BMGF CEO on February 1, 2020. [20]
In 2021, Desmond-Hellmann was appointed by President Joe Biden to the President’s Council of Advisors on Science and Technology (PCAST), co-chaired by Frances Arnold, Eric Lander and Maria Zuber. [21] In March 2024, Desmond-Hellman was appointed to OpenAI's Board of Directors. [22] In 2024 Desmond-Hellmann received the Clark Kerr Award for distinguished leadership in higher education from the UC Berkeley Academic Senate. [23]
Desmond-Hellmann married Nicholas Hellmann in 1987. [3]
The University of California, San Francisco (UCSF), is a public land-grant research university in San Francisco, California. It is part of the University of California system and is dedicated entirely to health science and life science. It conducts research and teaching in medical and biological sciences.
The Bill & Melinda Gates Foundation (BMGF) is an American private foundation founded by Bill Gates and Melinda French Gates. Based in Seattle, Washington, it was launched in 2000 and is reported to be the second largest charitable foundation in the world, holding $69 billion in assets as of 2020. The primary stated goals of the foundation are to enhance healthcare and reduce extreme poverty across the world, and to expand educational opportunities and access to information technology in the U.S. Key individuals of the foundation include Warren Buffett, chief executive officer Mark Suzman, and Michael Larson.
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.
Herbert Wayne "Herb" Boyer is an American biotechnologist, researcher and entrepreneur in biotechnology. Along with Stanley N. Cohen and Paul Berg, he discovered recombinant DNA, a method to coax bacteria into producing foreign proteins, which aided in jump-starting the field of genetic engineering.
Brook Byers is a senior partner at Kleiner Perkins Caufield & Byers and the brother of Stanford University Professor Tom Byers and Atlanta, Georgia engineering entrepreneur Ken Byers.
Elizabeth Helen Blackburn is an Australian-American Nobel laureate who is the former president of the Salk Institute for Biological Studies. In 1984, Blackburn co-discovered telomerase, the enzyme that replenishes the telomere, with Carol W. Greider. For this work, she was awarded the 2009 Nobel Prize in Physiology or Medicine, sharing it with Carol W. Greider and Jack W. Szostak, becoming the first Australian woman Nobel laureate.
John Michael Bishop is an American immunologist and microbiologist who shared the 1989 Nobel Prize in Physiology or Medicine with Harold E. Varmus. He serves as an active faculty member at the University of California, San Francisco (UCSF), where he also served as chancellor from 1998 to 2009.
Arthur D. Levinson is an American businessman and is the chairman of Apple Inc. (2011–present) and chief executive officer (CEO) of Calico. He is the former CEO (1995–2009) and chairman (1999–2014) of Genentech.
The University of California, Berkeley School of Public Health, also called Berkeley Public Health, is one of fourteen schools and colleges at the University of California, Berkeley. The school is currently accredited by the Council on Education for Public Health.
Axel Ullrich is a German cancer researcher and has been the director of the molecular biology department at the Max Planck Institute of Biochemistry in Martinsried, Germany since 1988. This department's research has primarily focused on signal transduction. Ullrich has received Hamdan Award for Medical Research Excellence, awarded by Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences, Dubai, United Arab Emirates in 2008 and Ullrich and his team received the Wolf Prize in 2010.
The President's Council of Advisors on Science and Technology (PCAST) is a council, chartered in each administration with a broad mandate to advise the president of the United States on science and technology. The current PCAST was established by Executive Order 13226 on September 30, 2001, by George W. Bush, was re-chartered by Barack Obama's April 21, 2010, Executive Order 13539, by Donald Trump's October 22, 2019, Executive Order 13895, and by Joe Biden's February 1, 2021, Executive Order 14007.
Jeffrey Scott Raikes is the co-founder of the Raikes Foundation. He retired from his role as the chief executive officer of the Bill & Melinda Gates Foundation in 2014. He serves on the boards of Giving Tech Labs, Hudl, Costco Wholesale, the Jeffrey S. Raikes School of Computer Science and Management at the University of Nebraska-Lincoln, and the Microsoft Alumni Network. He is chair of the Stanford University board of trustees. Until early 2008, Raikes was the president of the Microsoft Business Division and oversaw the Information Worker, Server & Tools Business and Microsoft Business Solutions Groups. He joined Microsoft in 1981 as a product manager. He retired from Microsoft in September 2008, after a transitional period, to join the Gates Foundation.
June Lee is an adjunct professor in the UCSF School of Medicine, biotech executive, and medical doctor with expertise in pulmonary, critical care medicine and translational research.
Alan Ashworth, FRS is a British molecular biologist, noted for his work on genes involved in cancer susceptibility. He is currently the President of the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, a multidisciplinary research and clinical care organisation that is one of the largest cancer centres in the Western United States. He was previously CEO of the Institute of Cancer Research (ICR) in London.
Life Sciences Foundation (LSF) was a San Francisco-based nonprofit organization that was established in 2011 to collect, preserve, interpret, and promote the history of biotechnology. LSF conducted historical research, maintained archives and published historically relevant materials and information.
DPR Construction Company is a commercial general contractor and construction management firm based in Redwood City, California. The privately-held, employee-owned company has 30 offices throughout the United States and specializes in projects for technology, life sciences, healthcare, higher education and commercial office markets. Its international offices were located in Europe and Asia.
The UCSF School of Medicine is the medical school of the University of California, San Francisco and is located at the base of Mount Sutro on the Parnassus Heights campus in San Francisco, California. Founded in 1864 by Hugh Toland, it is the oldest medical school in California and in the western United States.
Jeffrey A. Bluestone is an American researcher who is the A.W. and Mary Margaret Clausen Distinguished Professor Emeritus of Metabolism and Endocrinology at the University of California, San Francisco, and was previously executive vice chancellor and provost of that university. He began the UCSF affiliation in 2000, after earlier positions at the NCI-NIH, and at The University of Chicago.
A. Eugene Washington is an American physician, clinical investigator, and administrator. He served as the chancellor for health affairs at Duke University, and the president and chief executive officer of the Duke University Health System, from 2015 to 2023. His research considers gynaecology, health disparities, and public health policy. He was elected to the National Academy of Medicine in 1997 and the American Academy of Arts and Sciences in 2014.
Michelle R. Arkin is an American chemical biologist who is the Thomas William and Frederick John MacWilliam Distinguished Professor at the University of California, San Francisco (UCSF).